Inaugural Advisory Board Includes Internationally Renowned Experts In Oncology and Radiation Therapy BOSTON, MA and HAMILTON, ONTARIO, July 16, 2018 – Fusion…
Read More
BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced…
Read More
Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers Cambridge, UK and…
Read More
HAMILTON, ONTARIO – At the 2018 LSO Annual Awards Presentation event, Fusion Pharmaceuticals was awarded “Life Sciences Company of the Year.”…
Read More
BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today…
Read More
TORONTO– LSO today announced the recipients of its 2018 LSO Awards, recognizing outstanding individuals and companies contributing to the success…
Read More
HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it…
Read More
HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
Read More
Image-guided medicines for hard to treat cancers built using next generation medical isotopes TORONTO, ON (December 16, 2015) – FACIT…
Read More
HAMILTON, ONT. — 05/01/16 — Fusion Pharmaceuticals, Inc. (“Fusion”), a life sciences company focused on developing novel drugs for the…
Read More
